SCHEMBL6449503

SCHEMBL6449503

COc1c(F)cc(/C=C2/SC(=O)NC2=O)c(F)c1-c1cc2c(cc1C)C(C)(C)C=CC2(C)C

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 4/20 0.43
IGF1R P08069 4/20 0.42
TTR P02766 2/20 0.42
INSR P06213 1/20 0.42
GSK3B P49841 3/20 0.40
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
ATM Q13315 1/20 0.38
PIM1 P11309 3/20 0.38
PIM2 Q9P1W9 3/20 0.38
AKR1B1 P15121 2/20 0.38
GLS O94925 1/20 0.38
GLS2 Q9UI32 1/20 0.38
PDE4B Q07343 1/20 0.38
PIM3 Q86V86 1/20 0.38
GSK3A P49840 1/20 0.37
LMNA P02545 1/20 0.37
HPGD P15428 1/20 0.37
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6449509 1.00 PTPN1 (0.43) PTPN1IGF1RTTRINSRGSK3B
SCHEMBL14492595 0.90 PTPN1 (0.43) PTPN1IGF1RTTRINSRGSK3B
SCHEMBL5492859 0.90 PTPN1 (0.43) PTPN1IGF1RTTRINSRGSK3B
SCHEMBL5492857 0.90 PTPN1 (0.43) PTPN1IGF1RTTRINSRGSK3B
SCHEMBL6027961 0.85 PTPN1 (0.39) PTPN1IGF1RTTRINSRGSK3B
SCHEMBL6027964 0.85 PTPN1 (0.39) PTPN1IGF1RTTRINSRGSK3B
SCHEMBL5789478 0.82 RXRA (0.46) PTPN1IGF1RTTRINSRGSK3B
SCHEMBL5789476 0.82 RXRA (0.46) PTPN1IGF1RTTRINSRGSK3B
SCHEMBL6453680 0.81 PTPN1 (0.37) PTPN1IGF1RTTRINSRGSK3B
SCHEMBL6453677 0.81 PTPN1 (0.37) PTPN1IGF1RTTRINSRGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038098-A1 Substituted dihydronaphthalene and isochroman compounds for the treatment of metabolic disorders, cancer and other diseases INCYTE CORPORATION 2005-02-17 US claimed
US-20050038098-A1 Substituted dihydronaphthalene and isochroman compounds for the treatment of metabolic disorders, cancer and other diseases INCYTE CORPORATION 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038098-A1 Substituted dihydronaphthalene and isochroman compounds for the treatment of metabolic disorders, cancer and other diseases HSD17B10, IDH2, INSR PTPN1 1500/4885IGF1R 9/4885TTR 1357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.